


## PHARMACEUTICAL 2019

## **Monopar Therapeutics** Rank 57 of 363 RealRate









## PHARMACEUTICAL 2019





The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 115% points. The greatest weakness of Monopar Therapeutics is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 225%, being 188% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	7,318
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	400
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-2.4
Other Expenses	-72
Other Liabilities	0
Other Net Income	103
Other Revenues	0
Property and Equipment	0
Research and Development	1,774
Selling, General and Administrative Expense	1,628

Output Variable	Value in 1000 USD
Assets	7,318
Liabilities	400
Expenses	3,331
Revenues	0
Stockholders Equity	6,918
Net Income	-3,228
Comprehensive Net Income	-3,229
Economic Capital Ratio	225%

